Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) is under clinical investigation as a treatment for major depressive disorder. However, the mechanisms of action are unclear, and there is a lack of neuroimaging evidence, particularly among individuals with affective dysfunction. Furthermore, there is no direct causal evidence among humans that the prefrontal-amygdala circuit functions as described in animal models (ie, that increasing activity in prefrontal cortical control regions inhibits amygdala response to threat).
T he difficulty of treating highly comorbid mood and anxiety disorders 1 has led to increased clinical interest in potential alternative treatments, such as noninvasive brain stimulation techniques, including transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC). A recent meta-analysis 2 of individual data from 289 patients with major depressive disorder treated with tDCS showed that, compared with placebo-controlled clinical trials of antidepressant drugs, sham-controlled clinical trials of DLPFC tDCS had a similar number needed to treat (7 for response, 9 for remission). However, as with many antidepressant treatments, the mechanism of action is unclear. The prefrontal cortex is implicated in animal studies, which provide compelling evidence of its importance in regulating responses to threat via direct inhibition of the amygdala complex. In rodent models, the prefrontal cortex has been shown to inhibit aversive associations established in fear conditioning, with prefrontal lesions impeding 3 and prefrontal electrical stimulation enhancing 4 the extinction of a conditioned response. Furthermore, electrical prestimulation of the prefrontal cortex in rats and cats 5 specifically reduced amygdala responses. These preclinical models provide the foundation for theoretical models of emotional dysfunction in human disorders of anxiety and depression, in which deficient prefrontal control is believed to result in overactivity within areas responsible for assigning salience and attention to threatening stimuli, such as the amygdala. The amygdala is a critical component of the neural circuitry underlying fear processing. 6 Consistent with this, human neuroimaging studies have confirmed hyperactive amygdala and/ or hypoactive prefrontal activity in patients with anxiety disorders 7 and major depressive disorder. 8, 9 Furthermore, there is evidence that treatment with antidepressant drugs 10 or cognitive behavioral therapy 11 can reduce amygdala hyperactivity.
However, there is no direct causal evidence that the prefrontalamygdala circuit functions in humans as reported in animal models, that is, that increasing activity in prefrontal cortical control regions inhibits amygdala responses to threat. We combined DLPFC tDCS with functional magnetic resonance imaging (fMRI) of a specific cognitive task that recruits the prefrontal-amygdala circuit to perform a causal test of this hypothesis in a sample population of individuals with high trait anxiety. Transcranial direct current stimulation can be used to tonically increase or decrease cortical excitability using weak electrical currents. 12 Induced changes in tissue excitability can persist over minutes to hours after stimulation, effects that are N-methyl-D-aspartate receptor dependent and presumed to reflect changes in synaptic efficacy and plasticity. 13, 14 Initially used as a tool to induce changes in motor evoked potentials, tDCS has more recently been used to modulate cognition, such as attentional control 15 and working memory. 16 Neuroimaging indicates that DLPFC tDCS alters functional activation and connectivity in brain regions that support cognitive function, including regions distal from the stimulating electrodes. [17] [18] [19] Thus, the mechanism of action of DLPFC tDCS in the treatment of major depressive disorder may arise through the induction of plasticity in distributed cortical-striatal and limbic circuits, a network hypothesis that can only be assessed through combined neurostimulation and neuroimaging research. By use of stimulation to change the electrical state of cortical tissue, it becomes possible to test hypotheses about functional interactions between the cortex and connected subcortical structures 20 ; for example, it is possible to test the causal influence of the prefrontal cortex on regulation of the amygdala response to threat.
It has been shown through a behavioral study that bilateral DLPFC tDCS is associated with a reduction in vigilance to threat in an attentional task validated to predict the clinical response to anxiolytic drug treatment. 21 This reduction in attentional bias to threat has been replicated among healthy volunteers 22 and among individuals with social anxiety disorder. 23 We hypothesize that prefrontal stimulation increases cortical activity, which increases top-down attentional control of connected limbic structures, thus increasing regulation of the amygdala threat response. Davidson's model 24 proposes decreased activation in the left prefrontal cortex among individuals with major depressive disorder and anxiety-specific increased activation of the right prefrontal cortex. This hypothesis is supported with findings that right DLPFC stimulation with repetitive transcranial magnetic stimulation (rTMS) is associated with an increase in right amygdala activation 25 and that right DLPFC tDCS 26 and rTMS 27 are associated with an increase in attentional allocation to threatening stimuli. Excitation of the left DLPFC with tDCS 28,29 and rTMS 30 decreases attentional bias to threat, whereas inhibition of the left DLPFC with single-pulse TMS increases attentional bias to threat in individuals with anxiety. 31 To test this mechanistic hypothesis,
we assessed the effect of simultaneous left anodal and right cathodal DLPFC tDCS on neural threat reactivity measured with fMRI among a group of individuals with high trait anxiety during a wellvalidated, attentional control paradigm that was sensitive to anxiety-related differences in attentional function. Earlier work with this task across a range of trait anxiety has shown that individuals with high anxiety exhibit hypoactive prefrontal response and hyperactive amygdala response to fearful face distractors.
and fMRI to measure changes in the neural response to threat among a group of individuals with high trait anxiety. We used a single dose of the multisession tDCS protocol used in clinical trials of major depressive disorder. We predicted that DLPFC tDCS would modulate this pattern of activation and behavior. Specifically, we predicted that, under conditions of low attentional load with fearful distractors, receipt of tDCS would have 3 directional effects: an increase in cortical activation associated with attentional control, a decrease in amygdala activation, and an improvement in task accuracy. We stimulated bilateral DLPFC and then assessed changes in brain activity and behavior.
Methods

Participants
The study was approved by the University of Oxford Central University Research Ethics Committee. Eighteen female participants (all right handed; age range, 18-42 years; mean [SD] age, 23.1 [3.7] years) were recruited from the community. Female participants were chosen to avoid sex-related differences in brain activation during emotional tasks 33 and because there is a higher prevalence of anxiety disorders among women. 34 Participants were prescreened with an online version of the Spielberger State-Trait Anxiety Inventory (STAI). 35 Participants with high trait anxiety, defined as those who scored greater than 45 on the trait questionnaire (STAI-T), were invited for screening at the Warneford Hospital (Oxford, England), where they completed the Structured Clinical Interview for DSM-IV disorders. 36 Written informed consent was obtained from all participants, and data were deidentified. Participants who successfully met full screening requirements were invited to take part in 2 tDCS and fMRI scanning sessions at the John Radcliffe Hospital (Oxford, England). Additional details are given in the Trial Protocol in Supplement 1 and in Supplement 2.
Design
This trial used a within-participants double-blind design with 18 participants, each of whom attended 2 separate tDCS and fMRI sessions, randomized to stimulation order (real or sham tDCS followed by sham or real tDCS 1 month later, counterbalanced) ( Figure 1 ). On the day of the study, participants received tDCS while they sat at rest. After the stimulation ended, participants entered the scanner (mean time from tDCS offset to task onset, approximately 7 minutes) and performed the attentional control task.
Attentional Load Paradigm
The attentional load paradigm was adapted from Bishop et al.
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On each trial, a 6-letter string superimposed on a task-irrelevant unfamiliar face was presented for 200 milliseconds. The face stimuli comprised 4 different individuals with fearful or neutral expressions taken from the Pictures of Facial Affect.
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The task was to decide whether the letter string contained an X or an N. In one-half of the blocks (the high attentional load condition), the string comprised a single target letter (N or X) and 5 nontarget letters (H, K, M, W, and Z) arranged in random order. In the other half of the blocks, (the low attentional load condition), the letter string comprised 6 Xsor6Ns, which removed attentional search requirements. This manipulation of attentional load was identical to that used in earlier work 32,38 and conforms to Lavie's 39 description of cognitive effort.
The key hypothesis-driven condition of interest was low attentional load with fearful distractors. Earlier work showed that amygdala response to threat was observed only under the low attentional load condition in this task.
32 Therefore, by examining the effect of tDCS on brain regions selectively activated by this key hypothesis-driven contrast (fearful vs neutral face distractors under conditions of low attentional load), it was possible to test the hypothesis that tDCS reduces vigilance to threat in individuals with trait anxiety by altering frontolimbic activity and, specifically, by reducing amygdala response to fearful distractors.
Transcranial Direct Current Stimulation
Stimulation was delivered using a battery-powered device (DC Stimulator Plus; Neuroconn 40 ). The full parameters are given in Supplement 1 and Supplement 2.
Image Acquisition
Blood oxygenation level-dependent contrast functional images were acquired with echo-planar T2*-weighted imaging using a Siemens 3T Magnetom TrioTim syngo with a head coil gradient set. The full parameters are given in Supplement 2. Data were lost for 2 participants because of server issues, which reduced the analyzed sample to 16 participants (32 scans).
Statistical Analysis
The fMRI data processing was carried out using FEAT (FMRI Expert Analysis Tool), version 6.00, part of FSL (Functional MRI of the Brain Software Library). Registration to highresolution structural and standard space was carried out using FLIRT (FMRIB's Linear Image Registration Tool). 41, 42 Registration from high-resolution structural to standard space was then further refined using FNIRT (FMRIB's Nonlinear Image Registration Tool), 43 and motion correction was carried out with MCFLIRT, applying rigid-body transformations. Regressors for each condition yoked to trial onset were convolved with the canonical hemodynamic response function. An intermediate analysis was first performed, combining 3 runs into a single data set for each participant for each testing session (2 per participant). A within-subjects analysis was performed, and z (gaussian T) statistic images were thresholded using clusters determined by z > 2.3 and a (corrected) cluster significance threshold of P = .05. One-sample t tests were used to determine baseline effects (eg, fear vs neutral) in the sham condition only (1-tailed), and paired t tests were used to determine differences between the active and sham conditions (1-tailed). Small volume-corrected analyses were performed in bilateral amygdala regions of interest. The amygdala regions of interest were defined using the Harvard-Oxford Subcortical Structural Atlas (using a standard threshold including all voxels with >50% probability of lying within the amygdala). The hypothesis-driven contrasts analyzed are specified in Table 1 . Behavioral analysis was carried out using SPSS, version 24.0 (IBM Corp), with repeated measures analysis of variance (2-tailed) and follow up t tests (1-tailed). found that the right amygdala responds selectively during trials with fearful (vs neutral) distractors when attentional load is low (vs high), we first tested whether this baseline effect was replicated in the sham condition. As predicted, right amygdala activation occurred selectively during trials with fearful (not neutral) distractors only when attentional load was low (not high) (load low-high × emotion fear-neutral , z =3.06,P = .04, small volume correction) ( Figure 2B ). This finding confirmed that our emotional task was sufficiently sensitive to detect the expected presence of amygdala threat signaling in this sample of individuals with high trait anxiety. This baseline amygdala response was altered by tDCS. We tested for the predicted effect of tDCS, which was a reduction of amygdala signal for the contrast of fearful-neutral distractors under the low attentional load condition. Region-of-interest analysis revealed that, under the low attentional load condition only, bilateral DLPFC stimulation significantly reduced right amygdala threat response (tDCS real-sham × emotion fear-neutral , z =3.30, P = .04, small volume correction) (Figure 2A and C) . A similar reduction was observed in the left amygdala (z = 2.82, P = .04, small volume correction) (Figure 2A and C). Consistent with the absence of a baseline effect of fear in high attentional load trials, tDCS did not modify amygdala activation in response to fearful vs neutral faces under the high attentional load condition (tDCS real-sham × emotion fear-neutral, z <2.30,P > .05). Instead, tDCS reduced amygdala response to fearful vs neutral distractors selectively under the low attentional load condition.
Results
Data
Whole-brain analysis revealed that, contrary to the amygdala effect, stimulation significantly increased activation in frontal, temporal, and parietal clusters. The left frontal cluster extended from the frontal eye fields to dorsal premotor cortex (collectively, area 8 in the Sallet atlas; Oxford Centre for fMRI of the Brain Software Library), areas associated with attention and action selection 44 (tDCS real-sham × emotion fear-neutral , z =3.74,P < .001, whole-brain corrected) ( Figure 3A and B). In addition, clusters emerged in the right superior parietal lobule; the angular gyrus and supramarginal gyrus (key nodes of the dorsal attention network) (tDCS real-sham × emotion fear-neutral , z = 3.47, P < .001, wholebrain corrected) ( Figure 3A and B); and the temporoparietal junction (a key node of the ventral attention network 45 ) (tDCS real-sham × emotion fear-neutral , z =3.28,P < .001, whole-brain corrected) ( Figure 3A and B). Table 2 gives a summary of the results. Consistent with the absence of a baseline effect of fear and no effect of tDCS on high attentional load trials, tDCS did not modify wholebrain activation to fearful vs neutral faces in the high attentional load condition (tDCS real-sham × emotion fear-neutral ,z <2.30,P > .05). Instead, tDCS increased cortical response to fearful vs neutral distractors selectively under the low attentional load condition.
This task was optimized to drive differential activity in the prefrontal cortex and amygdala rather than to produce behavioral differences between conditions. However, earlier studies have reported marginal effects of anxiety on task behavior. Consistent with these findings, we compared task accuracy after real and sham tDCS. The tDCS × load × emotion interaction (F 1, 15 = 3.25, P = .09) showed a trend and thus we performed confirmatory analyses that suggest that, in the key condition in which there was a hypothesized effect of tDCS (low attentional load, fearful distraction trials), the contrast of real vs sham tDCS indicated a mean improvement in accuracy of 12.2% (95% CI, 0.30%-24. 
Discussion
In this sample population of women with high trait anxiety, DLPFC stimulation was associated with frontolimbic governance of at- ) provides the first experimental evidence, to our knowledge, for a direct causal inhibitory role of prefrontal cortex on amygdala threat response in individuals with trait anxiety. These findings suggest a mechanism of action that may contribute to the treatment effects of tDCS observed in clinical trials of affective disorders.
The amygdala is one of the key brain regions implicated in the pathophysiology of depression and anxiety disorders. Seminal preclinical research showed that conditioned fear is mediated by projections to the amygdala 47 Animal studies suggest that the amygdala response to threat is reduced by top-down inhibition from the prefrontal cortex. 4 Electric field modeling (Supplement 2) has shown that the montage used in this study may evoke the strongest electric field in the medial prefrontal cortex. This parallels preclinical research [3] [4] [5] that focused on the role of this region in downregulating amygdala threat response. Individuals with depression 9 21 indicates that DLPFC tDCS has the potential to reduce vigilance to threat. We investigated a neural mechanism that may mediate this effect. Earlier work 32 found that participants with high anxiety had increased amygdala and decreased prefrontal activation in response to fearful distractor faces under conditions of low attentional load compared with participants with low anxiety. The sample with high anxiety in our study showed a similar profile of amygdala response to fearful faces under the sham stimulation condition. As hypothesized, we found that DLPFC tDCS reduced this activation, such that, after stimulation, the findings among the group with high anxiety in the present study resembled the findings among the participants with low anxiety in the earlier study, with increased cortical and reduced amygdala response to threat distractors. Furthermore, confirmatory behavioral analyses indicated that this finding was accompanied by reduced attentional capture by threat distractors under low attentional load, which was reflected in increased accuracy after tDCS.
Repetitive transcranial magnetic stimulation of the DLPFC is a US Food and Drug Administration-approved treatment for depression, 57 and acute protocols have indicated associations between DLPFC rTMS and threat processing. 25 By contrast, the evidence base for clinical efficacy of DLPFC tDCS is still in development. If efficacy is established, tDCS offers several potential advantages over rTMS, including being better tolerated and being cheaper and simpler to administer, and the development of homeuse devices broadens potential patient uptake and clinical research. This proof-of-concept study used a single dose of the multisession tDCS protocol used in clinical trials of major depressive disorder and describes a neurocognitive mechanism of action of DLPFC tDCS in patients with trait anxiety that should be investigated in future therapeutic trial designs of clinical efficacy as a function of reducing hyperactive amygdala-dependent threat vigilance.
Limitations
The purpose of this study was to investigate acute effects of singlesession DLPFC tDCS by testing for an induced change in amygdala response to threat. Future work is required to determine whether these effects are extended over time when repeated tDCS interventions are used and to determine whether these acute changes in neurobehavioral markers of threat vigilance are predictive of clinical treatment response. Because of the increased 
BACKGROUND AND RATIONALE
This research will examine the effect of transcranial direct current brain stimulation (tDCS) and affective bias modification training on behavioural and brain imaging measures of emotional processing, anxiety and mood in healthy volunteers.
TDCS is a neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region (see further information on tDCS in section 8). This typically has acute effects relating to cortical activity levels which last up to one hour. There is a growing body of evidence suggesting that repeated An initial exploratory study was carried out (internal reference: 1301_MI) in 2012 to examine the effects of tDCS on emotional processing in healthy volunteers using a range of tasks and questionnaires. Using a dot probe task, which measures attention to happy or fearful faces, it was found that tDCS has the potential ability to reverse an attentional bias to fearful faces seen in the placebo group. This indicates that anxiety responses may be modified using tDCS and therefore this follow on study seeks to further explore the role of tDCS in anxiety and investigate the neural correlates of this with fMRI.
In the present study, it is intended to use behavioural and neuroimaging results to examine how tDCS affects emotional processing relevant to anxiety. A within-subjects design will increase the power of the study, given limited financial resources to carry out extensive neuroimaging. Our working hypothesis is that tDCS may boost activity in cortical regions relevant to attentional control and anxiety.
This study seeks to apply imaging techniques and validated behavioural tasks. A healthy participant group will be selected to take part in this research.
The findings of this study will be used to determine parameters for future patient studies, involving participants with generalized anxiety disorder or major depression. The ultimate aim, explored through further studies, is to understand and improve how tDCS might be used in the treatment of these disorders.
Risks and Benefits
TDCS has been used in hundreds of studies to date worldwide and is considered extremely safe, with (extremely rare) side effects. The researcher and qualified MRI operator will be on hand throughout the session, in case the participant wishes to stop the stimulation or scanning at any time.
In terms of a possibility of identifying psychological distress or disorder in non-NHS participants, MSD IDREC guidelines 1.1 are followed. Standardised techniques and mood questionnaires will be used 
OBJECTIVES AND OUTCOME MEASURES
STUDY DESIGN
This is a within-subjects, double blind, sham controlled study.
A within-subjects design was chosen to increase statistical power in the face of financial and time constraints to conduct an fMRI study within the timeframe of a DPhil. A female only cohort is sought to increase homogeneity.
Participation will involve a one hour screening session at Warneford hospital and two subsequent, two hour tDCS, fMRI and testing sessions at the University of Oxford Centre for Clinical Magnetic
Resonance Research (OCMR) at the John Radcliffe Hospital (see sequential study activities list below and section 7 for more information). Testing sessions will be at least one month apart and total participation will be over a period of not less than five weeks and not more than 13 weeks.
Sequential study activities
1. Online STAI-T questionnaire (at home). 2. Eligible participants will be contacted and invited to a screening session.
3. Screening session (1 visit, one hour, Warneford Hospital):
• Structured Clinical Interview for DSM-IV (SCID)
• Eysenck Personality Questionnaire (EPQ)
• National Adult Reading Test (NART)
• Beck Depression Inventory (BDI)
At the screening session a suitable time will be agreed for the two subsequent scan/testing sessions.
Visit 1 -1 st scan/testing session (2 hours, OCMR):
• Safety screening forms for tDCS and MRI.
• Self-report computerised questionnaires:
-tDCS and TMS Screening Questionnaire will be taken. In accordance with MSD/IDREC/2010/P17.2 participants are allowed to leave at any stage and whilst in the scanner subjects have easy access to a call button should they wish to stop the scan or speak with the operator. Risks associated with the magnetic field will be removed by carefully screening all subjects for ferromagnetic objects, metal implants and other metal (e.g. shrapnel injury) every time before they enter the scanner environment.
• Participants will be assisted out of the scanner and into an adjacent testing room where they will receive 20 mins 2mA tDCS/sham tDCS on the DLPFC (see section 8 for further info on tDCS)
• Participants will then be assisted back into the scanner.
• Behavioural tasks, completed inside the scanner (circa 40 minutes): • Participants will be assisted back out of the scanner
• Repeat STAI and VAS questionnaires 5. Visit 2-2nd scan/testing session (2 hours, OCMR).
• As per step 4, at least one month after the 1 st scan/testing session.
Questionnaire responses, behavioural and imaging data will be collected on computer.
PARTICIPANT IDENTIFICATION
Study Participants
Healthy females aged 18-45 years
Inclusion Criteria
• Participant is willing and able to give informed consent for participation in the study.
• Healthy female adults, right handed, aged 18-45 years.
• Participants will be asked to fill in a pre-screening online anxiety questionnaire (STAI-T) and will be invited to participate in the study if they score high within the normal range on trait anxiety.
Exclusion Criteria
The participant may not enter the study if ANY of the following apply:
• Any current significant medical condition.
• Any current or past psychological disorder (for example depression or anorexia).
• Any family history of extreme mood fluctuations (such as elated mood states) • Any current medications (except for contraceptive treatment) or herbal remedies such as St J
• Any current pregnancy or likelihood of becoming pregnant during the study.
• Any participation in any other psychological or medical experiment involving taking any kind of drugs, within the last 3 months.
• Previous participation in a brain stimulation study will be taken into account and advice will be sought from the secondary supervisor on whether they should be included, based on the type of stimulation received, the location of the stimulation and the number of sessions. If the secondary supervisor advises that the nature of the stimulation previously received could affect the results of this study, the participant will not be included.
• Participants should not be claustrophobic, have a heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body.
• Any other contraindication to MRI or TCS.
STUDY PROCEDURES
Recruitment
Participants will be recruited using posters and online advertisements. Interested parties will be directed to fill in an online pre-screening questionnaire or email the investigator for more information.
Informed Consent
The online pre-screening questionnaire will have a consent section, which allows informed consent for the initial pre-screening questionnaire. Alternatively return of the completed questionnaire would be implied consent for the pre-screening process.
Interested and eligible parties will be asked to come to the Warneford site for a one hour screening session. Participants will be sent an electronic copy of the participant information sheet and screening forms for tDCS and MRI at least 24 hours before the screening. The DPhil investigator (Maria Ironside) will obtain informed consent at the beginning of the screening session. The participant must personally sign and date the latest approved version of the Informed Consent form before any study specific procedures (including screening) are performed.
Written and verbal versions of the Participant Information and Informed Consent will be presented and explained to the participants detailing: the exact nature of the study; what it will involve for the participant; the implications and constraints of the protocol; the known side effects and any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and with no obligation to give the reason for withdrawal.
The participant will be allowed as much time as wished to consider the information, and the opportunity to question the Investigator, their GP or other independent parties to decide whether they will participate in the study. Written Informed Consent will then be obtained by means of participant dated signature and dated signature of the investigator. A copy of the signed Informed Consent will be given to the participant. The original signed form will be retained at the Warneford site.
Screening and Eligibility Assessment
Participants will be asked to fill in an online anxiety questionnaire (STAI-T) and will be invited to participate in a further screening if they score high within the normal range on trait anxiety. After obtaining Informed Consent, the investigator will take the participant through the Structured Clinical
Interview for DSM-IV disorders (SCID) to ensure that the eligibility criteria regarding current or prior psychological conditions are met. This is a standardized structured interview, used worldwide to assess the presence of any psychological disorders in humans. A medical history will also be taken, along with details of educational level. After this, participants will be asked to complete a computerised version of the Eysenck Personality Questionnaire (EPQ), a personality profiling tool and the Beck Depression Inventory (BDI), a standard depression questionnaire. If the screening is successful participants will be asked to agree a suitable time and date for the two scan/testing sessions. If the screening is unsuccessful participants will be offered information on other studies for which they may be eligible and will be reimbursed for their time and travel expenses. After screening, participants will be randomly allocated an order of testing sessions which they will attend. They will receive real stimulation at the first testing session and sham stimulation at the second testing session or the opposite order.
Randomisation, blinding and code-breaking
A sham setting on the tDCS device allows for a code to be entered before each stimulation session, w whether the participant is receiving real or sham stimulation.
A paper based blinding protocol will be prepared in advance which will set out a table with randomly assigned parameters for the total number of participants; and whether they will receive real or sham stimulation at each testing session. This blinding protocol will be kept in a specific filing cabinet for W A each participant (after they are successfully screened) to the next available slot on the blinding protocol sheet. The blinding investigator will fill in on a separate sheet the stimulation code for tDCS at each session. This information will be given to the experimenting investigator to enable them to conduct the study without knowing which parameters they are using. The investigator will not be un-blinded until all data has been collected, outliers in the data have been removed and the main analysis has been completed.
Visit 1
• At the initial scan/testing session, participants will be asked to fill out a tDCS safety screening form and an MRI safety screening form, to ensure there are no contraindications to tDCS or fMRI.
• Participants will next complete a series of standardised self-report mood questionnaires; commonly used in psychiatry research and practice. These will be completed online, on a laptop computer. o Visual analogue scale (VAS) scores for mood, asks for ratings on a scale of 1-10 for various emotions felt today.
These mood questionnaires (apart from BDI) will be repeated after stimulation.
• 20 mins 2mA tDCS/sham tDCS on the DLPFC, in a separate room adjacent to the MRI scanner (see section 8 for further info on tDCS)
• Computerised behavioural tasks to be carried out in the MRI scanner: • Repeat PANAS, STAI and VAS questionnaires.
Visit 2
• The second and final testing session will be structured exactly as the initial testing session outlined in section 7.5 (but with real or sham tDCS, depending on the protocol used in the first session). Safety screening forms will be completed again, along with details of any changes in medication or medical conditions in the intervening time period. Each participant has the right to withdraw from the study at any time and participants will be assured that they can withdraw from the study for any reason without penalty. In addition, the Investigator may discontinue a participant from the study at any time if the Investigator considers it necessary for any reason including:
Discontinuation/Withdrawal of Participants from Study
• Pregnancy
• Ineligibility (either arising during the study or retrospectively having been overlooked at screening)
• Significant protocol deviation
• Significant non-compliance with treatment regimen or study requirements
• Withdrawal of Consent
• Loss to follow up
Withdrawal from the study will result in exclusion of the data for that participant from analysis and withdrawn participants will be replaced until scanner slot availability makes this impossible.
The reason for withdrawal will be recorded in the CRF.
Definition of End of Study
The end of study is the date of the last scan/testing session of the last participant.
INTERVENTIONS
The participants will undergo tDCS in an adjacent room outside the MRI scanner environment and a subsequent MRI scan.
MRI
Imaging interventions: Once contraindications to magnetic resonance imaging are excluded, the risks of undergoing a scan are minimal. The tDCS and scanning will be carried out sequentially but separately, in adjacent rooms. An MR technician will go through a list of possible risks with the participant before scanning. The MRI scanner consists of a large powerful magnet. During the actual scanning procedure, the participant will hear loud banging noises. For that reason, the participant will be given earplugs and protective headphones. There is a small mirror or prism glasses that will allow the participant to view outside the scanner. Some people may find that being in the scanner is claustrophobic. All participants will therefore be given a chance to see the scanner to make sure that they are comfortable in it. During the whole duration of the experiment, the participant will be able to speak with the operators outside the scanner room through a microphone. In addition, they will be given a buzzer which allows him to stop the ongoing study at any time. Magnetic resonance imaging uses no ionising radiation. There are, however, potential hazards to those unsuitable to enter a magnetic environment. Anyone with metallic implants, pacemakers or with body piercing must be excluded. An exhaustive list of possible risks has been compiled and the volunteer checked against this by a radiographer prior to entering the secure area of the where the MRI scanners to be used in this study this study is located. People with a history of claustrophobia will be excluded from participation in the study. However, all participants will still be introduced carefully to the scanner and allowed to leave at any stage, should they wish to do so. Once in the scanner, participants will be able to indicate immediately if they wish the scanning to cease by squeezing a bulb placed in their hands, or by requesting it verbally.
MRI risks to participants:
Certain 3T MRI sequences can be very noisy so subjects will be given earplugs and/or ear-defenders.
The enclosed space of the scanner can induce feelings of claustrophobia. Any subject with a history of claustrophobia will be excluded. Other subjects will be introduced carefully to the scanner and allowed to leave at any stage. Whilst in the scanner subjects have easy access to a call button should they wish to stop the scan or speak with the operator.
Risks associated with the magnetic field will be removed by carefully screening all subjects for ferromagnetic objects, metal implants and other metal (e.g. shrapnel injury) every time before they enter the scanner environment.
Lying on the scanner table for prolonged times can induce temporary lower back pain. This will be minimised by means of comfortable padding and positioning.
ii) Ferromagnetic Objects:
Magnetic objects in or around the magnet will be tightly secured or MRI compatible in all cases to preclude projectile risks.
All researchers entering the magnet environment have undergone annual MRI safety testing to ensure maximal awareness and safety around the scanner and for each research volunteer. 
TDCS
Once contraindications to tDCS are excluded, the risks of taking part in a tDCS study are minimal. The investigator will go through a list of possible risks with the participant before the study and answer any questions. TDCS is used to directly and non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp. The current is generated by a battery-powered stimulator and passed through rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The electrodes will be located bilaterally on the dorsolateral prefrontal cortex (DLPFC), locations F3 and F4 in the 10/20 system of electrode placement.
The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localisation carried out using an EEG cap but no EEG imaging will be carried out). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). The possible minor side-effects of tingling, itching or a mild burning sensation under the electrode are more likely with the higher current densities so are less likely with this protocol. This protocol applies no more than 20 minutes of stimulation in a single session, which is typical for experimental studies. For sham stimulation, participants will receive 30 sec of direct current, followed by impedance control with a small current pulse A A During the whole duration of the experiment, the participant is able to talk with the investigator and indicate any discomfort. The MSD IDREC protocols for TCS (MSD/IDREC/2013/P22.1) will be adhered to throughout this study and the device to be used is CE marked as per protocol requirements (Neuroconn DC stimulator plus, Neuroconn GmbH). The experimenter is trained in first aid and is an experienced tDCS user.
SAFETY REPORTING
Definition of Serious Adverse Events
A serious adverse event is any untoward medical occurrence that:
• Results in death
• Is life-threatening NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. • Requires inpatient hospitalisation or prolongation of existing hospitalisation
• Results in persistent or significant disability/incapacity
• Is a congenital anomaly/birth defect.
• Other important medical events.* *Other events that may not result in death, are not life threatening, or do not require hospitalisation, may be considered a serious adverse event when, based upon appropriate medical judgement, the event may jeopardise the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.
Reporting Procedures for Serious Adverse Events
A serious adverse event (SAE) occurring to a participant should be reported to CTRG and the Medical Any unforeseen or adverse event will be dealt with according to MSD IDREC guideline 1.1, section 7, using the advised protocol and sample incident form given.
STATISTICS AND ANALYSIS
Description of Statistical Methods
Parametric tests will be used to analyse this data. SPSS statistical software will be used to carry out analysis of variance (ANCOVA) on the behavioural data, first comparing the active tDCS condition to sham (with order as a covariate). FMRIB Software Library v5.0 (FSL v5.0) will be used to analyse the neuroimaging data. The investigator will remain blind to the stimulation condition of each data set throughout the initial analysis phase. A sample size of 16 participants was chosen as a balance between manageability within the DPhil timeframe, recruitment and financial constraints and the need for sufficient power in an exploratory study.
The Number of Participants
Analysis of Outcome Measures
• Behavioural tests: A repeated measures analysis of variance (rm-ANCOVA) with stimulation condition and valence (of the stimuli in the behavioural tasks) as the within-subjects factors and order as a covariate.
• Neuroimaging data: Region of interest (ROI) based analysis will be carried out on a priori specified brain regions associated with cognitive control in anxiety (DLPFC, anterior cingulate cortex, fusiform face area, and amygdala). Following this whole brain analysis will be carried out to identify any clusters which were missed in the ROI approach. P values will be corrected for multiple comparisons.
• Test results in mood questionnaires: A repeated measures analysis of variance (rm-ANCOVA)
with stimulation condition as the within-subjects variable and order as a covariate.
• Behavioural and mood data will be correlated with imaging data to ascertain the neural correlates of task performance or mood, depending on stimulation condition.
DATA MANAGEMENT
Access to Data
Direct access will be granted to authorised representatives from the Sponsor for monitoring and/or audit of the study to ensure compliance with regulations.
Data Recording and Record Keeping
All behavioural study data will be entered on an Excel spreadsheet and neuroimaging data files will be kept electronically. The participants will be identified by a unique study specific number in any database.
The name and any other identifying detail will NOT be included in any study data electronic file.
All mood questionnaires will be carried out online using U O which adhere to data protection guidelines. Only the investigator will have access to this data. The only paper records associated with this study are the copies of the consent forms and the TCS/MRI safety screening questionnaires. These will be kept in a locked filing cabinet and destroyed after 10 years, in line with MSD IDREC guideline 2.1.
QUALITY ASSURANCE PROCEDURES
The study will be conducted in accordance with the current approved protocol, relevant regulations and standard operating procedures, in particular IDREC protocols for transcranial current stimulation (TCS) The study may be monitored, or audited in accordance with the current approved protocol, GCP, relevant regulations and standard operating procedures.
ETHICAL AND REGULATORY CONSIDERATIONS
Declaration of Helsinki
The Investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki.
Guidelines for Good Clinical Practice
The Investigator is trained in Good Clinical Practice will ensure that this study is conducted in accordance with relevant regulations and with Good Clinical Practice.
Approvals
The protocol, informed consent form, participant information sheet and any proposed advertising material will be submitted to an appropriate Research Ethics Committee (REC) for written approval.
The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents. The CI shall submit once a year throughout the study or on request, an Annual Progress report to the REC Committee, and Sponsor. In addition, an End of Study notification and final report will be submitted to the same parties.
Reporting
Participant Confidentiality
T T identified only by initials and a participants ID number on the CRF and any electronic database. All documents will be stored securely and only accessible by study staff and authorised personnel. The study will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical to do so.
Expenses and Benefits
Participants will be paid at a rate of £10 per hour for their participation in the research. Reasonable travel will be reimbursed on production of receipts, or a mileage allowance provided as appropriate.
Other Ethical Considerations
Due to the emotional content, there is a chance that the interview questionnaires or tasks could have the potential to make people feel upset. However, this approach has been used repeatedly in the Dept.
Psychiatry with no problems and in the event of any problems in this regard a clinical psychiatrist is available to advise the investigator.
As described above, tDCS is safe and well tolerated but some participants have complained of itching/pins and needles sensation under the electrodes. Participants will be well informed of what to expect and the experimenters will be on hand at all times to minimise the risk of any discomfort and, if required, stop the stimulation.
As described above, MRI is safe and well tolerated. Participants will be excluded for any contraindications to MRI (including claustrophobia) and will be familiarised to the scanner environment before scanning, to ensure comfort. A trained operator will be on hand at all times to ensure comfort and, if required, stop the scan. In the unlikely event of seeing any structural abnormalities on an MRI scan, a designated clinical specialist will discuss the implications with the participant and arrange for further investigations as necessary. However, it is important to note that scans are not carried out for diagnostic purposes, and therefore the scans are not a substitute for a clinical appointment. Rather, the scans are intended for research purposes only.
As part of the approval process this study is being reviewed by CUREC (Medical Sciences IDREC) and will not commence until approval is obtained.
FINANCE AND INSURANCE
Funding
The investigator is funded by an MRC studentship which includes a research and training support grant.
Additional participant expenses can be sought from departmental (Dept. Psychiatry) funding.
Insurance
The University has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting M L L L ndon).
PUBLICATION POLICY
The study forms part of a DPhil dissertation but may result in published papers (in scientific journals or at academic conferences) before this is finalised. The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Authors will acknowledge that the study was funded by the Medical Research Council. Authorship will be determined in accordance with the ICMJE guidelines and other contributors will be acknowledged.
At the testing session, the participants will be asked if they would like to receive details of the outcome after their session, and their preference will be noted on their consent form. If they so wish, an email will be sent with a summary of the test results after the entire study has been completed (this will not Participants who successfully met full screening requirements were invited to take part in two tDCS/MRI scanning sessions at the John Radcliffe Hospital, Oxford. Participants were compensated for their time at a rate of £10 per hour. For the present study we initially recruited sixteen participants, Data for two participants were partially lost due to server problems. These two participants were replaced to bring the total N recruited to eighteen and the dataset analysed to sixteen (Table S1 ). Formal sample size calculation was precluded, because no prior study had determined the effect of tDCS on brain activity in a high anxious sample. Hence, we estimated the likely effect size of tDCS, and the likely minimum sample size, informed by two prior related studies. Our previous work 1 showed that prefrontal tDCS reduced behavioral threat vigilance in healthy volunteers, with an effect size of Cohen d = 0.8737. Another previous work, using fMRI and the identical task paradigm to that used here, reported higher amygdala and lower prefrontal activation in a high versus low anxious sample 2 , with an effect size of Cohen d = 0.99. To detect effects of these magnitudes in the current repeated measures design 3 , a priori sample size calculation yielded N = 8 as the minimum sample size required to detect a reduction in amygdala fMRI signal (difference between two dependent means: matched pairs, one tailed, alpha =.05, dz = 0.99, power = .8), and N = 10 to detect a reduction in attention to threat behavior (difference between two dependent means: matched pairs, one tailed, alpha = .05, dz = 0.87, power = .8).
Design: A randomisation list was prepared by a colleague (Department of Psychiatry, University of Oxford) separate from the study and kept in a locked cabinet. Based on this randomisation list the experimenter was given a code to enter into the tDCS device which determined whether real or sham stimulation was delivered. Thus, the experimenter was blind to the stimulation order. On the day of the study participants first filled out mood questionnaires before being introduced to the scanner environment and undergoing a structural scan, during which they practiced a training version of the attentional control task. Then participants vacated the scanner and received tDCS in a separate room while they sat at rest. This allowed the participants to practice the task and become comfortable in the scanner environment to minimise time spent entering the scanner after tDCS.
Attentional load paradigm:
Visual stimuli were back-projected onto a translucent screen behind the bore of the magnet, visible via an angled mirror placed above the participant's head. In the present study the face stimuli comprised four different individuals with fearful and neutral expressions taken from the Pictures of Facial Affect 4 and cropped to remove extraneous background information. The neutral faces were morphed using computer graphics to have a neutral: happy expression mix of 30:70%, because wholly neutral faces have previously been found to be aversive 5 . The experiment was performed using Presentation® software (Version 14.0, Neurobehavioral Systems, Inc., Berkeley, CA).
On each trial, a string of 6 letters was superimposed on a task-irrelevant face distractor presented in the centre of the screen. Participants had to indicate whether the letter string contained an "X" or an "N". A target was present on every trial.
The task was to decide whether the letter string contained an "X" or an "N". In half the blocksthe "high attentional load" condition -the string comprised a single target letter (N or X) and 5 non-target letters (H, K, M, W, Z) arranged in random order. In the other half of blocks-the ''low attentional load" condition-the letter string comprised 6 Xs or 6 Ns, reducing attentional search requirements. This manipulation of attentional load is identical to the one used in Bishop and others 2 , Jenkins and others 6 and conforms to Lavie's 7 description of heightening cognitive effort by: 1) increasing the number of different identity items that need to be perceived, or 2) making perceptual identification more demanding on attention. The rationale for these load conditions is that when the task is undemanding, greater distractibility puts higher demands on attentional control.
A mixed block/event-related design was used -the level of attentional load (high or low) was varied across blocks, while the expression of the task-irrelevant face distractors (fearful or neutral) was varied across trials. These 2 factors (attentional load × distractor emotion) resulted in 4 conditions: high load/fearful distractors; high load/neutral distractors; low load/fearful distractors; low load/neutral distractors. The key hypothesis-driven condition of interest was: low load/fearful distractors. Previous work has shown that amygdala response to threat is observed only in the low load condition in this task 2 . Therefore, by examining the effect of tDCS on brain regions selectively activated by this key hypothesisdriven contrast (fearful versus neutral face distractors under conditions of low load) it was possible to test the hypothesis that tDCS reduces vigilance to threat in trait anxiety by altering fronto-limbic activity; specifically, by reducing amygdala response to fearful distractors.
There were 3 imaging acquisition runs, each comprising 12 blocks of 4 trials. There was a 2 s interval between blocks. Within blocks, the inter-stimulus interval was randomly jittered using an exponential function with a mean of 4.5 s and a minimum of 3 s.
Transcranial Direct Current Stimulation (tDCS):
Stimulation was delivered using a battery powered device (DC Stimulator Plus, Neuroconn, Germany 8 ). The rubber electrodes (5cm x 5cm) were placed in saline soaked sponges and affixed to the scalp with a rubber band. We used a bipolar-balanced electrode montage which positioned the anode (positive) electrode on the left dorsolateral prefrontal cortex and the cathode (negative) electrode on the right dorsolateral prefrontal cortex (F3 and F4 respectively, 10/20 system of electrode placement). In the real/active tDCS condition, stimulation (20 minutes at 2mA) was applied while the participant sat at rest. In the sham condition participants received 30 s of direct current, followed by impedance control with a small current pulse every 550 ms (110 A over 15 ms) instead of the stimulation current, resulting in an instantaneous current of not more than 2 A or 40 sec of active stimulation. This method of sham stimulation produced the physical sensations typical of real tDCS and displayed realistic impedance values on the device display. The experimenter was thus blind to the stimulation condition, facilitated by a 'study' mode for blinding on the device. Modelling of the electric field evoked by tDCS was carried out using SimNIBS software 9 and a standard anatomical brain model. As previously reported 10 , the modelling suggests that that the strongest field is evoked in the medial prefrontal cortex (see Fig. S1 ).
